Global intensity modulated radiotherapy market is anticipated to grow at a CAGR of 8.7% during the forecast period (2023-2030). The rapid adoption of new treatments in the field of oncology and innovative treatments for various types of cancer drive the market of intensity modulated radiation therapy in the near future. Improvements in both computer technology and imaging techniques have enabled the rapid development of this exciting treatment modality. Advances in radiation therapy technology have led to more precise and targeted treatments. Techniques such as intensity-modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT), and proton therapy allow for highly focused radiation delivery, sparing healthy tissues and minimizing side effects.
Browse the full report description of “Intensity Modulated Radiotherapy Market Size, Share & Trends Analysis Report by Radiation Type (Photon Radiation, Electron Beam Radiation, Proton Radiation, and Carbon ion Radiation), by Application (Prostate Cancer, Breast Cancer, Lung Cancer, Gastrointestinal Cancer, and Other Cancer), and by End Users (Hospitals and Speciality Center), Forecast Period (2023-2030)” at https://www.omrglobal.com/industry-reports/intensity-modulated-radiotherapy-market
The increasing prevalence of different cancers such as prostate, breast cancer lung cancer, and other is driving the demand for Intensity-modulated radiotherapy (IMRT). According to the National Institute of Health (NIH), in March 2023, Global Cancer Observatory (GLOBOCAN) estimated, there were 19.3 million incident cancer cases globally for the year 2020. India ranked third after China and the US. GLOBOCAN predicted that cancer cases in India would increase to 2.08 million, accounting for a rise of 57.5% in 2040 from 20202.
The new radiopaque version can be seen on computerized tomography (CT) scans, negating the need for physicians to include magnetic resonance imaging (MRI) in the treatment planning, and accommodating patients who are contra-indicated for MRI. For instance, in October 2022, Royal Philips, in health technology, launched two new advances in MR-only workflows to advance head and neck cancer radiotherapy imaging and simulation. Treatment of soft tissue tumors in the head and neck, along with the brain, pelvis, and prostate, has received FDA 510(k) clearance and is commercially available in the US.
Market Coverage
• The market number available for – 2022-2030
• Base year- 2022
• Forecast period- 2023-2030
• Segment Covered-
o By Radiation Type
o By Application
o By End Users
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- Hitachi, Ltd., Koninklijke Philips N.V., Siemens Healthineers AG., Accuray, Inc., Hitachi, Ltd., Mevion Medical Systems., Sumitomo Heavy Industries, Ltd., and Varian Medical Systems, Inc.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Intensity Modulated Radiotherapy Market Report Segment
By Radiation Type
By Application
By End Users
Global Intensity Modulated Radiotherapy Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/intensity-modulated-radiotherapy-market